CompanyGraph
Sign in
Biotechnology

Biotechnology

Binary regulatory approval gates determine whether a decade of R&D investment produces revenue or write-offs, concentrating economic outcomes around pipeline success rates and patent exclusivity windows.

The biotechnology industry converts biological research into approved medical products through a multi-stage development process spanning preclinical research, clinical trials, regulatory review, and manufacturing scale-up. The defining structural characteristic is the length, cost, and uncertainty of this pipeline: a typical drug candidate requires over a decade of development, with attrition rates exceeding 90% across clinical phases, meaning most invested capital yields no commercial product.

This risk profile shapes the capital structure of the industry. Pre-revenue companies fund development through equity issuance, venture capital, and licensing partnerships, relying on external capital willingness to accept binary outcomes. Once products reach market, revenue dynamics depend on pricing, payer reimbursement, physician adoption, and competitive alternatives, all within the finite window of patent-protected exclusivity before biosimilar entry erodes pricing.

Manufacturing biological products requires specialized facilities with stringent quality controls and cold-chain logistics, adding capital and operational complexity beyond the research and approval stages. Regulatory oversight governs the entire lifecycle from development through post-market surveillance, creating a persistent compliance infrastructure requirement that scales with the number of approved products and active clinical programs.

Structural Role

Coordinates the translation of biological science into approved medical products, managing multi-year development pipelines with high attrition rates across clinical stages to deliver treatments that address unmet medical needs within regulated healthcare systems.

Scale Differentiation

Large biotechnology companies operate diversified product portfolios that fund ongoing R&D from commercial revenue, reducing dependence on external capital. Mid-size companies typically have one or a few commercial products alongside pipeline candidates at various stages. Smaller companies are often pre-revenue, entirely dependent on equity issuance and partnerships to fund clinical development through approval and commercialization.

Constraint Archetype

Approval-Gated Pipeline

A regime where products must pass through extended, binary regulatory approval processes before generating any revenue, concentrating economic outcomes around gate decisions rather than market competition.

Financial Profile

Measured across the 476 companies in this industry with recorded financial statements. Each band spans the middle 90% of companies — 5th to 95th percentile — with the mark at the median. How wide a band runs is itself a reading: a tight band means the industry imposes its economics on every member; a wide one means outcomes differ sharply between its strongest and weakest companies.

Profitability

Gross margin74.5%median
14.6%99.9%
Operating margin-26.5%median
0
-4699.7%42.2%
Net margin-30.8%median
0
-4801.4%42.5%

Returns & efficiency

Return on equity-22.4%median
0
-176.1%28.2%
Asset turnover0.14×median
0.00×0.71×
Free cash flow / revenue-37.5%median
0
-3372.7%42.2%

Balance sheet

Current ratio5.26×median
0.97×22.60×
Debt to equity0.10×median
0.00×1.61×

Reinvestment & payout

R&D / revenue40.7%median
3.6%3488.7%
Capex / revenue5.1%median
0.1%56.0%

What marks this industry

Where this industry’s typical company sits against the typical company in every other industry we measure — metric by metric.

Return on equity
-22.4%typical industry 7.1%

1st lowest of 102 industries with this measure.

Free cash flow / revenue
-37.5%typical industry 1.5%

1st lowest of 101 industries with this measure.

Net margin
-30.8%typical industry 5.4%

1st lowest of 101 industries with this measure.

Operating margin
-26.5%typical industry 8.1%

1st lowest of 101 industries with this measure.

Scale

453
companies with recorded market value
$1.2B
median company · global median $1.2B
$280M – $12.6B
middle 90% of companies
$1.9T
combined market value

The largest member carries roughly 8% of the combined market value; half the companies sit under $1.2B.

Valuation ranges

Price to book4.47×median
1.17×29.16×
Price to earnings35.58×median
6.74×253.34×

EV / EBITDA bands are not drawn for this industry. Many members run negative values there, and a percentile band across mixed signs has no honest reading — a range is shown only where it means something.

Bands are 5th–95th percentiles across this industry’s companies, computed from reported financial statements. Ratios are currency-free; money values are USD-normalized. These distributions describe how the industry is shaped — they are not a rating of it, and a company’s position inside them is not a forecast. Benchmark set computed 19 September 2026.

Connected Industries

Capital Markets

Creates demand for

Equity financing for pre-revenue companies

Diagnostics & Research

Creates demand for

Lab equipment and clinical testing

Drug Manufacturers General

Supplies inputs to

Licenses or supplies biologics to pharma

Drug Manufacturers Specialty & Generic

Regulates

Patent expiry enables biosimilar competition

Medical Care Facilities

Supplies inputs to

Specialty therapeutics for hospitals

Scientific & Technical Instruments

Creates demand for

Research instrumentation

Stocks